125 related articles for article (PubMed ID: 37932204)
1. Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9).
Damassi A; Cremante M; Signori A; Rebuzzi SE; Fornarini G; Giudice GC; Maruzzo M; Procopio G; Sorarù M; Di Napoli M; Fratino L; Santini D; Grillone F; Ballestrin M; Dionese M; Nasso C; Catalano F; Murianni V; Rescigno P; Anpalakhan S; Banna GL; Basso U; Buti S
Clin Genitourin Cancer; 2024 Apr; 22(2):126-133.e2. PubMed ID: 37932204
[TBL] [Abstract][Full Text] [Related]
2. Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib.
Rebuzzi SE; Cerbone L; Signori A; Santoni M; Murianni V; De Giorgi U; Procopio G; Porta C; Milella M; Basso U; Massari F; Maruzzo M; Iacovelli R; Battelli N; Carmisciano L; Banna GL; Buti S; Fornarini G
Ther Adv Med Oncol; 2022; 14():17588359221079580. PubMed ID: 35237353
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program.
Rebuzzi SE; Signori A; Buti S; Banna GL; Murianni V; Damassi A; Maruzzo M; Giannarelli D; Tortora G; Galli L; Rizzo M; De Giorgi U; Antonuzzo L; Bracarda S; Cartenì G; Atzori F; Tamberi S; Procopio G; Fratino L; Lo Re G; Santoni M; Baldessari C; Astone A; Calabrò F; Brunelli M; Porta C; Rescigno P; Basso U; Fornarini G
ESMO Open; 2022 Dec; 7(6):100634. PubMed ID: 36493602
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).
Rebuzzi SE; Signori A; Banna GL; Maruzzo M; De Giorgi U; Pedrazzoli P; Sbrana A; Zucali PA; Masini C; Naglieri E; Procopio G; Merler S; Tomasello L; Fratino L; Baldessari C; Ricotta R; Panni S; Mollica V; Sorarù M; Santoni M; Cortellini A; Prati V; Soto Parra HJ; Stellato M; Atzori F; Pignata S; Messina C; Messina M; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Roviello G; Pierantoni F; Casadei C; Bersanelli M; Chiellino S; Paolieri F; Perrino M; Brunelli M; Iacovelli R; Porta C; Buti S; Fornarini G
Ther Adv Med Oncol; 2021; 13():17588359211019642. PubMed ID: 34046089
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.
Rebuzzi SE; Signori A; Banna GL; Gandini A; Fornarini G; Damassi A; Maruzzo M; De Giorgi U; Basso U; Chiellino S; Galli L; Zucali PA; Fantinel E; Naglieri E; Procopio G; Milella M; Boccardo F; Fratino L; Pipitone S; Ricotta R; Panni S; Mollica V; Sorarù M; Santoni M; Cortellini A; Prati V; Soto Parra HJ; Santini D; Atzori F; Di Napoli M; Caffo O; Messina M; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Roviello G; Rescigno P; Buti S
J Transl Med; 2022 Sep; 20(1):435. PubMed ID: 36180954
[TBL] [Abstract][Full Text] [Related]
6. Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab:
Murianni V; Signori A; Buti S; Rebuzzi SE; Bimbatti D; De Giorgi U; Chiellino S; Galli L; Zucali PA; Masini C; Naglieri E; Procopio G; Milella M; Fratino L; Baldessari C; Ricotta R; Mollica V; Sorarù M; Tudini M; Prati V; Malgeri A; Atzori F; Di Napoli M; Caffo O; Spada M; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Lipari H; Roviello G; Catalano F; Damassi A; Cremante M; Rescigno P; Fornarini G; Banna GL
Front Oncol; 2024; 14():1307635. PubMed ID: 38410103
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
[TBL] [Abstract][Full Text] [Related]
8. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
[TBL] [Abstract][Full Text] [Related]
9. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
[TBL] [Abstract][Full Text] [Related]
10. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
11. Observational study on the evolution of systemic treatments for advanced renal cell carcinoma in Southwest Finland between 2010 and 2021.
Hölsä O; Teittinen K; Anttalainen A; Ukkola-Vuoti L; Summanen M; Mattila KE
Ther Adv Urol; 2023; 15():17562872231206243. PubMed ID: 37941979
[TBL] [Abstract][Full Text] [Related]
12. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.
Santoni M; Massari F; Bracarda S; Grande E; Matrana MR; Rizzo M; De Giorgi U; Basso U; Aurilio G; Incorvaia L; Martignetti A; Molina-Cerrillo J; Mollica V; Rizzo A; Battelli N
Eur Urol Focus; 2022 Nov; 8(6):1696-1702. PubMed ID: 35193819
[TBL] [Abstract][Full Text] [Related]
14. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.
Albiges L; Fléchon A; Chevreau C; Topart D; Gravis G; Oudard S; Tourani JM; Geoffrois L; Meriaux E; Thiery-Vuillemin A; Barthélémy P; Ladoire S; Laguerre B; Perrot V; Billard A; Escudier B; Gross-Goupil M
Eur J Cancer; 2021 Jan; 142():102-111. PubMed ID: 33253997
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
Santoni M; Aurilio G; Massari F; Grande E; Matrana MR; Rizzo M; De Giorgi U; Incorvaia L; Martignetti A; Molina-Cerrillo J; Zabalza IO; Mollica V; Rizzo A; Battelli N; Porta C
Clin Genitourin Cancer; 2022 Jun; 20(3):285-295. PubMed ID: 35305916
[TBL] [Abstract][Full Text] [Related]
16. Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27.
Stellato M; Buti S; Maruzzo M; Bassanelli M; Bersanelli M; Napoli MD; Dionese M; Fanelli M; Filippi R; Fotia G; Galli L; Grillone F; Maffezzoli M; Maiorano BA; Nasso C; Rebuzzi SE; Lalli L; Roviello G; Sorarù M; Vincenzi B; Procopio G; Verzoni E
Clin Genitourin Cancer; 2024 Mar; 22(3):102078. PubMed ID: 38631104
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma.
Sato R; Matsushita Y; Takemura A; Sugiyama M; Watanabe K; Watanabe H; Tamura K; Motoyama D; Nagata M; Otsuka A; Furuse H; Miyake H
Anticancer Res; 2024 Feb; 44(2):781-786. PubMed ID: 38307571
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
Takagi T; Fukuda H; Kondo T; Ishihara H; Yoshida K; Kobayashi H; Iizuka J; Okumi M; Ishida H; Tanabe K
Target Oncol; 2019 Apr; 14(2):179-186. PubMed ID: 30927174
[TBL] [Abstract][Full Text] [Related]
19. Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score.
Mazzaschi G; Lazzarin A; Santoni M; Trentini F; Giorgi U; Brighi N; Tommasi C; Puglisi S; Caffo O; Kinspergher S; Mennitto A; Cattrini C; Verzoni E; Rametta A; Stellato M; Malgeri A; Roviello G; Silini EM; Rescigno P; Rebuzzi SE; Fornarini G; Quaini F; Giudice GC; Banna GL; Buti S
Front Biosci (Elite Ed); 2023 Jul; 15(3):20. PubMed ID: 37743233
[TBL] [Abstract][Full Text] [Related]
20. Real-world data on the efficacy and safety of pazopanib in IMDC favorable- and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective cohort study of Chinese patients.
Anwaier A; Chen J; Zhou H; Zhao X; Zheng S; Li X; Qu Y; Shi G; Zhang H; Wu J; Ye D
Transl Androl Urol; 2022 May; 11(5):694-709. PubMed ID: 35693709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
